Outlook Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

OTLK Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001649989 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$160.68M
243,447,554 shares Covers every share class this company has on file.
Insiders on file
1
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$9.04M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
5.63%
insider-held value divided by market capitalisation

What Outlook Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$1.41M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$62.42M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
17
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Outlook Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

People who file insider reports against Outlook Therapeutics, Inc..
Insider Reported role Shares Value Last action
Ghiath M Sukhtian Board Member 13,552,359 $9.04M P Open-market purchase Aug 12, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Outlook Therapeutics, Inc. (OTLK) filed a Form 8-K under Item 5.02 (directors and officers) on Aug 27, 2026

Director or officer change filing

The company filed a current report that includes Item 5.02, the item used to report departures, elections or appointments of directors and certain officers, and related pay arrangements. We record only that this filing exists: we have not extracted who left, who joined or whose role changed. Open the filing to read it.

Form 8-K filed Aug 27, 2026, items 5.02, 9.01. SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 5 rows we hold, 3 are open-market purchases (P) and 0 open-market sales — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Outlook Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 12, 2026 Ghiath M Sukhtian P Open-market purchase 2,525,252 $0.99 $2.50M SEC filing ↗
May 28, 2026 Ghiath M Sukhtian P Open-market purchase 8,539,709 $0.59 $5.04M SEC filing ↗
May 26, 2026 Kurt J. Hilzinger P Open-market purchase 400,000 $0.44 $176.0K SEC filing ↗
May 27, 2025 Ghiath M Sukhtian A Grant or award 4,285,714 $1.40 $6.00M SEC filing ↗
Jan 17, 2025 Ghiath M Sukhtian M Option exercise or conversion 3,458,571 $2.51 $8.68M SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 2 filers hold a position

Who owns Outlook Therapeutics, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 1 of the positions below was reported on a filing shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Outlook Therapeutics, Inc.

Funds, trusts and companies that disclose an ownership position in Outlook Therapeutics, Inc..
Owner Reported role Shares Filed
GMS Ventures & Investments Director,TenPercentOwner 13,552,359 joint
Syntone Ventures LLC TenPercentOwner 1,705,438

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 5 legal entities

Subsidiaries of Outlook Therapeutics, Inc.

5 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries Outlook Therapeutics, Inc. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Outlook Therapeutics CH GmbH Switzerland
Outlook Therapeutics DE GmbH Germany
Outlook Therapeutics Limited England and Wales
Outlook Therapeutics NL B.V. Netherlands
Outlook Therapeutics Pty Ltd Australia
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Outlook Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Outlook Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.